COMMUNIQUÉS West-GlobeNewswire

Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
17/06/2026
Lead Cell Therapy Demonstrated Complete Tumor Clearance and 100% Long-Term Survival in Preclinical Ovarian Cancer Models; Multiple Regulatory, Manufacturing and Clinical Catalysts Expected Through 2027 CAMBRIDGE, Mass [...]
MedX Holdings Accelerates Growth: Expanding Lazydaze Franchise Footprint, Unveiling Major Product Innovations, and Strengthening Brand Infrastructure
17/06/2026
Lazydaze Coffeeshop - Here We Grow Again Austin Texas, June 17, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MedX Holdings Accelerates Growth Strategy: Expanding Lazydaze Franchise Footprint, Unveiling Major Product [...]
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
17/06/2026
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to report topline data from Seabreeze STAT Asthma study in early September 2026 – – Strong balance sheet with cash runway [...]
Polyrizon Receives Notice of U.S. Patent Publication for Mucoadhesive Drug Delivery Platform
17/06/2026
Raanana, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, [...]
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
17/06/2026
100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapy Complete [...]
BPGbio Presents Latest Clinical and Translational Findings Supporting BPM31510 in Primary CoQ10 Deficiency at Mito Med 2026
17/06/2026
Presentations highlight clinical outcomes in pediatric PCQD subjects and translational evidence supporting tissue delivery and mitochondrial metabolic correction Data support planned Phase 3 pivotal trial in PCQD [...]
Zelluna ASA: Contemplated Private Placement and Retail Offering to Strengthen its Position Ahead of Initial Clinical Data
17/06/2026
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE [...]
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026
17/06/2026
Per May 2026 Type C meeting, AXPAXLI NDA for wet AMD to be based on SOL-1 Week 52 efficacy and safety plus interim SOL-R safety data Ocular to conduct interim SOL-R safety analysis in 4Q 2026 to reach >300 patients [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
17/06/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 17 June 2026 at 16.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Glass House Brands Announces its Deconsolidation of its Dual-Use Business and its Application for Uplisting of Shares to NYSE
17/06/2026
LONG BEACH, Calif. and TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- Glass House Brands Inc. ("Glass House" or the “Company”) (CBOE CA: GLAS.A.U) (OTCQX: GLASF) today announced that it has applied to list its subordinate [...]
Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc.
17/06/2026
- Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Dyne [...]
Trading in GN Store Nord shares by board members, executives and associated persons
17/06/2026
GN Store Nord has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in GN Store Nord made by persons discharging managerial responsibilities in GN [...]
Trevi Therapeutics Announces Upcoming June and July Event Schedule
17/06/2026
NEW HAVEN, Conn., June 17, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the [...]
BrewDog Turns Up Father’s Day Across the U.K. with Gift-Ready Beer, Custom Cans and Dads Eat Free
17/06/2026
From standout beer gifts to nationwide bar experiences, BrewDog is bringing bold flavour and big Father’s Day energy to dads across the U.K. ELLON, Scotland, June 17, 2026 (GLOBE NEWSWIRE) -- Scottish brewer, BrewDog , [...]
CorVel Launches Marketwise Repricing™ to Deliver Smarter, Market-Based Medical Cost Containment
17/06/2026
A data-driven repricing solution that optimizes cost management and complements existing bill review workflows FORT WORTH, Texas, June 17, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (Nasdaq: CRVL), a national provider [...]
Avricore Health Closes $1.254 Million Financing
17/06/2026
VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore” ) announces that, further to its news release dated May 20, 2026, the Company has closed its [...]
uniQure Announces Plan for BLA Submission for AMT-130 in Huntington’s Disease
17/06/2026
~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter of 2026 ~ LEXINGTON [...]
Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering
17/06/2026
Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexibility Additional proceeds used to pay for the capped call with a premium of 100% and to repurchase $25 million of [...]
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
17/06/2026
Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a [...]

Pages